Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views.

Maher TM, Swigris JJ, Kreuter M, Wijsenbeek M, Cassidy N, Ireland L, Axmann J, Nathan SD.

Respiration. 2018 Aug 16:1-11. doi: 10.1159/000490667. [Epub ahead of print]

PMID:
30114692
2.

Needs, Perceptions and Education in Sarcoidosis: A Live Interactive Survey of Patients and Partners.

Moor CC, van Manen MJG, van Hagen PM, Miedema JR, van den Toorn LM, Gür-Demirel Y, Berendse APC, van Laar JAM, Wijsenbeek MS.

Lung. 2018 Oct;196(5):569-575. doi: 10.1007/s00408-018-0144-4. Epub 2018 Aug 7.

3.

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.

Flaherty KR, Fell CD, Huggins JT, Nunes H, Sussman R, Valenzuela C, Petzinger U, Stauffer JL, Gilberg F, Bengus M, Wijsenbeek M.

Eur Respir J. 2018 Aug 2;52(2). pii: 1800230. doi: 10.1183/13993003.00230-2018. Print 2018 Aug. Erratum in: Eur Respir J. 2018 Oct 4;52(4):.

4.

Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry.

Baughman RP, Shlobin OA, Wells AU, Alhamad EH, Culver DA, Barney J, Cordova FC, Carmona EM, Scholand MB, Wijsenbeek M, Ganesh S, Birring SS, Kouranos V, O'Hare L, Baran JM, Cal JG, Lower EE, Engel PJ, Nathan SD.

Respir Med. 2018 Jun;139:72-78. doi: 10.1016/j.rmed.2018.04.015. Epub 2018 May 5.

PMID:
29858005
5.

A home monitoring program including real-time wireless home spirometry in idiopathic pulmonary fibrosis: a pilot study on experiences and barriers.

Moor CC, Wapenaar M, Miedema JR, Geelhoed JJM, Chandoesing PP, Wijsenbeek MS.

Respir Res. 2018 May 29;19(1):105. doi: 10.1186/s12931-018-0810-3.

6.

Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.

Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Santin-Janin H, Mulder GJ, Bartholmai B, Gupta R, Richeldi L.

JAMA. 2018 Jun 12;319(22):2299-2307. doi: 10.1001/jama.2018.6129.

PMID:
29800034
7.

Fibrocytes are increased in lung and peripheral blood of patients with idiopathic pulmonary fibrosis.

Heukels P, van Hulst JAC, van Nimwegen M, Boorsma CE, Melgert BN, van den Toorn LM, Boomars KAT, Wijsenbeek MS, Hoogsteden H, von der Thüsen JH, Hendriks RW, Kool M, van den Blink B.

Respir Res. 2018 May 10;19(1):90. doi: 10.1186/s12931-018-0798-8.

8.

Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes.

Broos CE, Koth LL, van Nimwegen M, In 't Veen JCCM, Paulissen SMJ, van Hamburg JP, Annema JT, Heller-Baan R, Kleinjan A, Hoogsteden HC, Wijsenbeek MS, Hendriks RW, van den Blink B, Kool M.

Eur Respir J. 2018 Mar 1;51(3). pii: 1701124. doi: 10.1183/13993003.01124-2017. Print 2018 Mar.

PMID:
29449421
9.

Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis.

Kreuter M, Costabel U, Richeldi L, Cottin V, Wijsenbeek M, Bonella F, Bendstrup E, Maher TM, Wachtlin D, Stowasser S, Kolb M.

Respiration. 2018;95(5):317-326. doi: 10.1159/000486286. Epub 2018 Feb 7.

PMID:
29414827
10.

Daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis.

Broos CE, Wapenaar M, Looman CWN, In 't Veen JCCM, van den Toorn LM, Overbeek MJ, Grootenboers MJJH, Heller R, Mostard RL, Poell LHC, Hoogsteden HC, Kool M, Wijsenbeek MS, van den Blink B.

Eur Respir J. 2018 Jan 18;51(1). pii: 1702089. doi: 10.1183/13993003.02089-2017. Print 2018 Jan. No abstract available.

PMID:
29348185
11.

Development and feasibility of an eHealth tool for idiopathic pulmonary fibrosis.

Moor CC, van Manen MJG, Tak NC, van Noort E, Wijsenbeek MS.

Eur Respir J. 2018 Mar 29;51(3). pii: 1702508. doi: 10.1183/13993003.02508-2017. Print 2018 Mar. No abstract available.

PMID:
29348156
12.

Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis.

Moor CC, Heukels P, Kool M, Wijsenbeek MS.

Front Med (Lausanne). 2017 Dec 20;4:226. doi: 10.3389/fmed.2017.00226. eCollection 2017. Review.

13.

Th17-lineage cells in pulmonary sarcoidosis and Löfgren's syndrome: Friend or foe?

Miedema JR, Kaiser Y, Broos CE, Wijsenbeek MS, Grunewald J, Kool M.

J Autoimmun. 2018 Feb;87:82-96. doi: 10.1016/j.jaut.2017.12.012. Epub 2018 Jan 5. Review.

PMID:
29310925
14.

Clubbing in patients with fibrotic interstitial lung diseases.

van Manen MJG, Vermeer LC, Moor CC, Vrijenhoeff R, Grutters JC, Veltkamp M, Wijsenbeek MS.

Respir Med. 2017 Nov;132:226-231. doi: 10.1016/j.rmed.2017.10.021. Epub 2017 Nov 2.

PMID:
29229102
15.

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.

Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U.

Eur Respir Rev. 2017 Dec 6;26(146). pii: 170057. doi: 10.1183/16000617.0057-2017. Print 2017 Dec 31. Review.

16.

No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis.

Broos CE, Poell LHC, Looman CWN, In 't Veen JCCM, Grootenboers MJJH, Heller R, van den Toorn LM, Wapenaar M, Hoogsteden HC, Kool M, Wijsenbeek MS, van den Blink B.

Respir Med. 2018 May;138S:S31-S37. doi: 10.1016/j.rmed.2017.10.022. Epub 2017 Oct 31.

PMID:
29137908
17.

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis.

van Manen MJG, Birring SS, Vancheri C, Vindigni V, Renzoni E, Russell AM, Wapenaar M, Cottin V, Wijsenbeek MS.

Eur Respir J. 2017 Oct 19;50(4). pii: 1701157. doi: 10.1183/13993003.01157-2017. Print 2017 Oct. No abstract available.

18.

Palliative care in interstitial lung disease: living well.

Kreuter M, Bendstrup E, Russell AM, Bajwah S, Lindell K, Adir Y, Brown CE, Calligaro G, Cassidy N, Corte TJ, Geissler K, Hassan AA, Johannson KA, Kairalla R, Kolb M, Kondoh Y, Quadrelli S, Swigris J, Udwadia Z, Wells A, Wijsenbeek M.

Lancet Respir Med. 2017 Dec;5(12):968-980. doi: 10.1016/S2213-2600(17)30383-1. Epub 2017 Oct 13. Review.

19.

A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.

Birring SS, Wijsenbeek MS, Agrawal S, van den Berg JWK, Stone H, Maher TM, Tutuncu A, Morice AH.

Lancet Respir Med. 2017 Oct;5(10):806-815. doi: 10.1016/S2213-2600(17)30310-7. Epub 2017 Sep 8.

20.

Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study.

Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, Grutters J, Inoue Y, Kokosi M, Kondoh Y, Kouranos V, Kreuter M, Johannson K, Judge E, Ley B, Margaritopoulos G, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Ryerson CJ, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts W, Hansell D, Wells A; IPF Project Consortium.

Eur Respir J. 2017 Aug 31;50(2). pii: 1700936. doi: 10.1183/13993003.00936-2017. Print 2017 Aug.

PMID:
28860269
21.

Patient and partner empowerment programme for idiopathic pulmonary fibrosis.

van Manen MJG, van 't Spijker A, Tak NC, Baars CT, Jongenotter SM, van Roon LR, Kraan J, Hoogsteden HC, Wijsenbeek MS.

Eur Respir J. 2017 Apr 26;49(4). pii: 1601596. doi: 10.1183/13993003.01596-2016. Print 2017 Apr. No abstract available.

PMID:
28446554
22.

Development and Pretesting of a Questionnaire to Assess Patient Experiences and Satisfaction with Medications (PESaM Questionnaire).

Kimman ML, Rotteveel AH, Wijsenbeek M, Mostard R, Tak NC, van Jaarsveld X, Storm M, Wijnsma KL, Gelens M, van de Kar NCAJ, Wetzels J, Dirksen CD.

Patient. 2017 Oct;10(5):629-642. doi: 10.1007/s40271-017-0234-z.

23.

What patients with pulmonary fibrosis and their partners think: a live, educative survey in the Netherlands and Germany.

van Manen MJ, Kreuter M, van den Blink B, Oltmanns U, Palmowski K, Brunnemer E, Hummler S, Tak NC, van den Toorn L, Miedema J, Hoogsteden HC, Wijsenbeek MS.

ERJ Open Res. 2017 Feb 14;3(1). pii: 00065-2016. doi: 10.1183/23120541.00065-2016. eCollection 2017 Jan.

24.

Optimizing quality of life in patients with idiopathic pulmonary fibrosis.

van Manen MJ, Geelhoed JJ, Tak NC, Wijsenbeek MS.

Ther Adv Respir Dis. 2017 Mar;11(3):157-169. doi: 10.1177/1753465816686743. Epub 2017 Jan 1. Review. Erratum in: Ther Adv Respir Dis. 2017 Jun;11(6):245.

25.

[A rare form of obstructive pulmonary disease].

van Loenhout CJ, den Bakker MA, van Wijsenbeek MS, Hoek RA, van Hal PT.

Ned Tijdschr Geneeskd. 2016;160:D757. Dutch.

PMID:
28074734
26.

Translation and validation of the King's Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch.

Wapenaar M, Patel AS, Birring SS, Domburg RTV, Bakker EW, Vindigni V, Sköld CM, Cottin V, Vancheri C, Wijsenbeek MS.

Chron Respir Dis. 2017 May;14(2):140-150. doi: 10.1177/1479972316674425. Epub 2016 Dec 26.

27.

Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns.

Kreuter M, Wijsenbeek MS, Vasakova M, Spagnolo P, Kolb M, Costabel U, Weycker D, Kirchgaessler KU, Maher TM.

Eur Respir J. 2016 Nov;48(5):1524-1526. doi: 10.1183/13993003.01482-2016. No abstract available.

28.

[German Validation of the "King's Brief Interstitial Lung Disease (K-Bild) Health Status Questionnaire"].

Kreuter M, Birring SS, Wijsenbeek M, Wapenaar M, Oltmanns U, Costabel U, Bonella F.

Pneumologie. 2016 Nov;70(11):742-746. Epub 2016 Sep 21. German.

PMID:
27652583
29.

Cough in idiopathic pulmonary fibrosis.

van Manen MJ, Birring SS, Vancheri C, Cottin V, Renzoni EA, Russell AM, Wijsenbeek MS.

Eur Respir Rev. 2016 Sep;25(141):278-86. doi: 10.1183/16000617.0090-2015. Review.

30.

European idiopathic pulmonary fibrosis Patient Charter: a missed opportunity.

Bonella F, Wijsenbeek M, Molina-Molina M, Duck A, Mele R, Geissler K, Wuyts W.

Eur Respir J. 2016 Jul;48(1):283-4. doi: 10.1183/13993003.00604-2016. No abstract available.

31.

New insights on patient-reported outcome measures in idiopathic pulmonary fibrosis: only PROMises?

Wijsenbeek M, van Manen M, Bonella F.

Curr Opin Pulm Med. 2016 Sep;22(5):434-41. doi: 10.1097/MCP.0000000000000294. Review.

PMID:
27333428
32.

Medical Therapy in Idiopathic Pulmonary Fibrosis.

Antoniou KM, Wuyts W, Wijsenbeek M, Wells AU.

Semin Respir Crit Care Med. 2016 Jun;37(3):368-77. doi: 10.1055/s-0036-1582010. Epub 2016 May 27. Review.

PMID:
27231861
33.

Acetylcysteine in IPF: the knockout blow?

Wijsenbeek MS, Collard HR.

Lancet Respir Med. 2016 Jun;4(6):420-1. doi: 10.1016/S2213-2600(16)30085-6. Epub 2016 May 5. No abstract available.

PMID:
27161256
34.

Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis.

Kreuter M, Wijsenbeek MS, Vasakova M, Spagnolo P, Kolb M, Costabel U, Weycker D, Kirchgaessler KU, Maher TM.

Eur Respir J. 2016 Jun;47(6):1776-84. doi: 10.1183/13993003.02087-2015. Epub 2016 Apr 21. Erratum in: Eur Respir J. 2016 Aug;48(2):593.

35.

Validation of the King's Sarcoidosis Questionnaire (KSQ) in a Dutch sarcoidosis population.

Van Manen MJ, Wapenaar M, Strookappe B, Drent M, Elfferich M, de Vries J, Gosker HR, Birring SS, Patel AS, van den Toorn L, van den Blink B, Boomars K, Hoitsma E, Wijsenbeek MS.

Sarcoidosis Vasc Diffuse Lung Dis. 2016 Mar 29;33(1):75-82.

PMID:
27055839
36.

Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy.

van den Blink B, Dillingh MR, Ginns LC, Morrison LD, Moerland M, Wijsenbeek M, Trehu EG, Bartholmai BJ, Burggraaf J.

Eur Respir J. 2016 Mar;47(3):889-97. doi: 10.1183/13993003.00850-2015. Epub 2016 Feb 11.

37.

Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives.

Kreuter M, Bonella F, Wijsenbeek M, Maher TM, Spagnolo P.

Biomed Res Int. 2015;2015:329481. doi: 10.1155/2015/329481. Epub 2015 Dec 8. Review.

38.

Treatment of Sarcoidosis.

Wijsenbeek MS, Culver DA.

Clin Chest Med. 2015 Dec;36(4):751-67. doi: 10.1016/j.ccm.2015.08.015. Review.

PMID:
26593147
39.

European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers.

Bonella F, Wijsenbeek M, Molina-Molina M, Duck A, Mele R, Geissler K, Wuyts W.

Eur Respir J. 2016 Feb;47(2):597-606. doi: 10.1183/13993003.01204-2015. Epub 2015 Nov 19.

40.

Cultural Differences in Palliative Care in Patients With Idiopathic Pulmonary Fibrosis.

Wijsenbeek M, Bendstrup E, Ross J, Wells A.

Chest. 2015 Aug;148(2):e56. doi: 10.1378/chest.15-0705. No abstract available.

PMID:
26238839
41.

Challenges in the classification of fibrotic ILD: Patient case 2.

Wijsenbeek M.

Sarcoidosis Vasc Diffuse Lung Dis. 2015 Aug 3;32 Suppl 1:13-6.

PMID:
26237438
42.

Challenges in the classification of fibrotic ILD.

Bendstrup E, Maher TM, Manali ED, Wijsenbeek M.

Sarcoidosis Vasc Diffuse Lung Dis. 2015 Aug 3;32 Suppl 1:4-9. Review.

PMID:
26237436
43.

Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis.

Wijsenbeek MS, Grutters JC, Wuyts WA.

Adv Ther. 2015 Jul;32(7):691-704. doi: 10.1007/s12325-015-0225-1. Epub 2015 Jul 15.

44.

[Idiopathic pulmonary fibrosis: new insights].

Kraan JW, van den Blink B, van den Toorn LM, Bresser P, van Beek FT, Grutters JC, Wijsenbeek MS.

Ned Tijdschr Geneeskd. 2015;159:A8148. Review. Dutch.

PMID:
25654681
45.

Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.

Judson MA, Baughman RP, Costabel U, Drent M, Gibson KF, Raghu G, Shigemitsu H, Barney JB, Culver DA, Hamzeh NY, Wijsenbeek MS, Albera C, Huizar I, Agarwal P, Brodmerkel C, Watt R, Barnathan ES.

Eur Respir J. 2014 Nov;44(5):1296-307. doi: 10.1183/09031936.00000914. Epub 2014 Jul 17.

46.

Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis.

Dillingh MR, van den Blink B, Moerland M, van Dongen MG, Levi M, Kleinjan A, Wijsenbeek MS, Lupher ML Jr, Harper DM, Getsy JA, Hoogsteden HC, Burggraaf J.

Pulm Pharmacol Ther. 2013 Dec;26(6):672-6. doi: 10.1016/j.pupt.2013.01.008. Epub 2013 Feb 4.

PMID:
23380438
47.

"Tree in bud" attributable to organising pneumonia.

Bots EM, den Bakker MA, Wijsenbeek MS, van den Toorn LM, van den Blink B.

Thorax. 2013 Apr;68(4):399-400. doi: 10.1136/thoraxjnl-2012-202064. Epub 2012 Jul 27. No abstract available.

PMID:
22843557
48.

Serum biomarkers in idiopathic pulmonary fibrosis.

van den Blink B, Wijsenbeek MS, Hoogsteden HC.

Pulm Pharmacol Ther. 2010 Dec;23(6):515-20. doi: 10.1016/j.pupt.2010.08.001. Epub 2010 Aug 12. Review.

PMID:
20708704

Supplemental Content

Loading ...
Support Center